PDF下载 ( 337 KB)
Interferon-free therapy, oral medication, and global cure: a new era for treatment of chronic hepatitis C
-
摘要:
慢性丙型肝炎可导致肝脏慢性炎症、坏死和纤维化,部分患者可发展为肝硬化甚至肝细胞癌,严重威胁人类健康和生命安全。近几年,欧美对丙型肝炎治疗的新药,尤其是直接靶向小分子治疗药物的研发及应用非常迅速。无干扰素,口服治疗,全面治愈已成为慢性丙型肝炎治疗的现实。简述了小分子丙型肝炎药物的优点及不足,影响小分子药物靶向治疗的因素以及目前美国食品药品监督管理局已批准的直接靶向小分子药物治疗方案及其相关进展。
Abstract:Hepatitis C Virus( HCV) Infection affects approximately 170 million people globally,that causes chronic hepatitis C and has been associated with cirrhosis and hepatocellular carcinoma. In the past few years,significant advances have been made in development and clinical application of direct anti-viral agents( DAA) that have been demonstrated highly safe and effective with very high sustained virological response( SVR) rates. This article provides systemic review in this field,especially USA FDA approved DAA regimens for HCV treatment.
-
Key words:
- hepatitis C,chronic /
- antiviral agents /
- directacting antivirals /
- editorial
-
本文二维码
计量
- 文章访问数: 315
- HTML全文浏览量: 17
- PDF下载量: 77
- 被引次数: 0
下载:
